The United States has initiated a trade investigation into Germany's drug pricing and spending on new medicines, announced Thursday by the Office of the US Trade Representative. The probe follows months of bilateral talks that did not yield a resolution and targets planned German health reforms. [Euronews] [Financial Times]
No left-leaning sources covered this
No right-leaning sources covered this
The probe represents an attempt to shield pharmaceutical profits by pressuring Germany to increase spending on medicines and slow its health reforms.
“US trade policy captured by industry interests that externalize high domestic prices”
The investigation corrects long-standing European price suppression that allows foreign systems to benefit from US innovation without contributing proportionally.
“Protection of intellectual property and market incentives against foreign cost controls”
Government-to-government pressure distorts voluntary transactions and substitutes political leverage for decentralized pricing between firms and buyers.
“Removal of state interventions including patents, FDA barriers, and trade enforcement”
All prior framings accept unsubstantiated claims of unique US subsidization of global R&D without examining actual cost data or sovereign purchasing authority.
“Questioning the trade-law vehicle and untested assumptions about innovation incentives”
Ratings by MBFC